<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antiepileptics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int276-antiepileptics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int276-antiepileptics.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int276-antiepileptics.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int911-pioglitazone.htm" title="Previous: Pioglitazone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1195-retigabine.htm" title="Next: Retigabine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Antiepileptics</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Antiepileptics</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>anticonvulsant effect of </span> <span>antiepileptics</span> <span>antagonised by</span> <span>SSRIs</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>anticonvulsant effect of </span> <span>antiepileptics</span> <span>antagonised by</span> <span>tricyclics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int252-antidepressants-tricyclic-related.htm">Antidepressants, Tricyclic (related)</a></td><td class="cAI"><p><span>anticonvulsant effect of </span> <span>antiepileptics</span> <span>possibly antagonised by</span> <span>tricyclic-related antidepressants</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td class="cAI"><p><span>anticonvulsant effect of </span> <span>antiepileptics</span> <span>antagonised by</span> <span>antipsychotics</span> <span>(convulsive threshold lowered)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>anticonvulsant effect of </span> <span>antiepileptics</span> <span>possibly antagonised by</span> <span>MAOIs</span> <span>(convulsive threshold lowered)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span>anticonvulsant effect of </span> <span>antiepileptics</span> <span>antagonised by</span> <span>mefloquine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int856-orlistat.htm">Orlistat</a></td><td class="cAI"><p><span>possible increased risk of convulsions when </span> <span>antiepileptics</span> <span>given with</span> <span>orlistat</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>antiepileptics</span> <span>with</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Retigabine</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>increased risk of blurred vision when </span> <span>retigabine</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>retigabine</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>retigabine</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Phenobarbital</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>abacavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>increased sedative effect when </span> <span>phenobarbital</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly accelerates metabolism of</span> <span>tricyclics</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>probably reduces effects of</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>phenobarbital</span> <span>possibly increased by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int550-carbonic-anhydrase-inhibitors.htm">Carbonic Anhydrase Inhibitors</a></td><td><p><span>increased risk of osteomalacia when </span> <span>phenobarbital</span> <span>given with</span> <span>carbonic anhydrase inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int158-chloramphenicol.htm">Chloramphenicol</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly accelerates metabolism of</span> <span>chloramphenicol</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int374-chlorpromazine.htm">Chlorpromazine</a></td><td><p><span>plasma concentration of both drugs reduced when </span> <span>phenobarbital</span> <span>given with</span> <span>chlorpromazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>ciclosporin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int408-clonazepam.htm">Clonazepam</a></td><td><p><span></span> <span>phenobarbital</span> <span>often reduces plasma concentration of</span> <span>clonazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>corticosteroids</span> <span>(reduced effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>coumarins</span> <span>(reduced anticoagulant effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>darunavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>disopyramide</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int212-doxycycline.htm">Doxycycline</a></td><td><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>doxycycline</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int281-ethosuximide.htm">Ethosuximide</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>ethosuximide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1031-etoposide.htm">Etoposide</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>etoposide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int860-folates.htm">Folates</a></td><td><p><span>plasma concentration of </span> <span>phenobarbital</span> <span>possibly reduced by</span> <span>folates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>gefitinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int291-griseofulvin.htm">Griseofulvin</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces absorption of</span> <span>griseofulvin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>haloperidol</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>indinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>irinotecan</span> <span>and its active metabolite</span>  </p></td><td></td></tr><tr><td><a href="bnf_int472-isradipine.htm">Isradipine</a></td><td><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>isradipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>lamotrigine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>lopinavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td><p><span>plasma concentration of </span> <span>phenobarbital</span> <span>possibly increased by</span> <span>methylphenidate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int170-metronidazole.htm">Metronidazole</a></td><td><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>metronidazole</span> <span>(reduced effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to topical metronidazole preparations </p></div></td></tr><tr><td><a href="bnf_int254-mianserin.htm">Mianserin</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>mianserin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int845-montelukast.htm">Montelukast</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>montelukast</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int476-nimodipine.htm">Nimodipine</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>nimodipine</span> <span>(plasma concentration of <span>nimodipine</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td><p><span>plasma concentration of </span> <span>phenobarbital</span> <span>increased by</span> <span>oxcarbazepine</span> <span>, also plasma concentration of an active metabolite of <span>oxcarbazepine</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int59-paracetamol.htm">Paracetamol</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly accelerates metabolism of</span> <span>paracetamol</span> <span>(also isolated reports of hepatotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>paroxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>phenobarbital</span> <span>often increased by</span> <span>phenytoin</span> <span>, plasma concentration of <span>phenytoin</span> often reduced but may be increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>posaconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>propranolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1102-rufinamide.htm">Rufinamide</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>rufinamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1067-sodium-oxybate.htm">Sodium Oxybate</a></td><td><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>sodium oxybate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1144-stiripentol.htm">Stiripentol</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenobarbital</span> <span>increased by</span> <span>stiripentol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>telithromycin</span> <span>(avoid during and for 2 weeks after <span>phenobarbital</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>theophylline</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>thyroid hormones</span> <span>(may increase requirements for <span>thyroid hormones</span> in hypothyroidism)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int857-tiagabine.htm">Tiagabine</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>tiagabine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>topiramate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int582-toremifene.htm">Toremifene</a></td><td><p><span></span> <span>phenobarbital</span> <span>accelerates metabolism of</span> <span>toremifene</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>phenobarbital</span> <span>increased by</span> <span>valproate</span> <span>(also plasma concentration of <span>valproate</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td><p><span>avoidance of </span> <span>phenobarbital</span> <span>advised by manufacturer of</span> <span>vandetanib</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int768-vitamin-d.htm">Vitamin D</a></td><td><p><span></span> <span>phenobarbital</span> <span>possibly increases requirements for</span> <span>vitamin D</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>phenobarbital</span> <span>possibly reduces plasma concentration of</span> <span>voriconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1040-zonisamide.htm">Zonisamide</a></td><td><p><span></span> <span>phenobarbital</span> <span>reduces plasma concentration of</span> <span>zonisamide</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Primidone</strong> belongs to <strong>Antiepileptics</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Primidone interactions as for phenobarbital</p></div><p><strong>Eslicarbazepine</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>eslicarbazepine</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span>but risk of side-effects increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>eslicarbazepine</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td><p><span>manufacturer of </span> <span>eslicarbazepine</span> <span>advises avoid concomitant use with</span> <span>oxcarbazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>eslicarbazepine</span> <span>reduced by</span> <span>phenytoin</span> <span>, also plasma concentration of <span>phenytoin</span> increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>eslicarbazepine</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>eslicarbazepine</span> <span>reduces plasma concentration of</span> <span>simvastatin</span> <span>—consider increasing dose of <span>simvastatin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span></span> <span>eslicarbazepine</span> <span>reduces plasma concentration of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Stiripentol</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>stiripentol</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int409-clobazam.htm">Clobazam</a></td><td><p><span></span> <span>stiripentol</span> <span>increases plasma concentration of</span> <span>clobazam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span></span> <span>stiripentol</span> <span>increases plasma concentration of</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>stiripentol</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Lacosamide</strong> belongs to <strong>Antiepileptics</strong> but has no specific interaction information.</p><p><strong>Rufinamide</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of both drugs possibly reduced when </span> <span>rufinamide</span> <span>given with</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>rufinamide</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>rufinamide</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>rufinamide</span> <span>possibly reduced by</span> <span>phenytoin</span> <span>, also plasma concentration of <span>phenytoin</span> possibly increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>rufinamide</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>rufinamide</span> <span>possibly increased by</span> <span>valproate</span> <span>(reduce dose of <span>rufinamide</span>)</span>  </p></td><td></td></tr></tbody></table><p><strong>Zonisamide</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>zonisamide</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>zonisamide</span> <span>reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>zonisamide</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Carbamazepine</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>increased by</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>CNS side-effects of </span> <span>carbamazepine</span> <span>possibly increased by</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>tricyclics</span> <span>(reduced plasma concentration and reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>aripiprazole</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int469-calcium-channel-blockers-dihydropyridines.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td><p><span></span> <span>carbamazepine</span> <span>probably reduces effects of</span> <span>dihydropyridines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int947-caspofungin.htm">Caspofungin</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>caspofungin</span> <span>—consider increasing dose of <span>caspofungin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>ciclosporin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>metabolism of </span> <span>carbamazepine</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>increased by</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int408-clonazepam.htm">Clonazepam</a></td><td><p><span></span> <span>carbamazepine</span> <span>often reduces plasma concentration of</span> <span>clonazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>clozapine</span> <span>(reduced plasma concentration), also avoid concomitant use of drugs with substantial potential for causing agranulocytosis</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>corticosteroids</span> <span>(reduced effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>coumarins</span> <span>(reduced anticoagulant effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>dabigatran etexilate</span> <span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int579-danazol.htm">Danazol</a></td><td class="cAI"><p><span>metabolism of </span> <span>carbamazepine</span> <span>inhibited by</span> <span>danazol</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>darunavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int90-dextropropoxyphene.htm">Dextropropoxyphene</a></td><td class="cAI"><p><span>effects of </span> <span>carbamazepine</span> <span>enhanced by</span> <span>dextropropoxyphene</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span>effects of </span> <span>carbamazepine</span> <span>enhanced by</span> <span>diltiazem</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>increased risk of hyponatraemia when </span> <span>carbamazepine</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int212-doxycycline.htm">Doxycycline</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>doxycycline</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of both drugs reduced when </span> <span>carbamazepine</span> <span>given with</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1205-eribulin.htm">Eribulin</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>eribulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>increased by</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1153-eslicarbazepine.htm">Eslicarbazepine</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>eslicarbazepine</span> <span>but risk of side-effects increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int281-ethosuximide.htm">Ethosuximide</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>ethosuximide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int471-felodipine.htm">Felodipine</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces effects of</span> <span>felodipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>possibly increased by</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>gefitinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>haloperidol</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>imatinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>indinavir</span> <span>, also plasma concentration of <span>carbamazepine</span> possibly increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>irinotecan</span> <span>and its active metabolite</span>  </p></td><td></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>increased by</span> <span>isoniazid</span> <span>(also possibly increased <span>isoniazid</span> hepatotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int684-isotretinoin.htm">Isotretinoin</a></td><td><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>possibly reduced by</span> <span>isotretinoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int472-isradipine.htm">Isradipine</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces effects of</span> <span>isradipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>possibly increased by</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td><p><span></span> <span>carbamazepine</span> <span>often reduces plasma concentration of</span> <span>lamotrigine</span> <span>, also plasma concentration of an active metabolite of <span>carbamazepine</span> sometimes raised (but evidence is conflicting)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>lapatinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int913-levetiracetam.htm">Levetiracetam</a></td><td><p><span>possible increased risk of </span> <span>carbamazepine</span> <span>toxicity when given with</span> <span>levetiracetam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>neurotoxicity may occur when </span> <span>carbamazepine</span> <span>given with</span> <span>lithium</span> <span>without increased plasma concentration of <span>lithium</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>lopinavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>manufacturer of </span> <span>carbamazepine</span> <span>advises avoid for 2 weeks after stopping</span> <span>MAOIs</span> <span>, also antagonism of anticonvulsant effect</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int254-mianserin.htm">Mianserin</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>mianserin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int299-miconazole.htm">Miconazole</a></td><td><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>possibly increased by</span> <span>miconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>midazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td><p><span></span> <span>carbamazepine</span> <span>antagonises muscle relaxant effect of</span> <span>non-depolarising muscle relaxants</span> <span>(accelerated recovery from neuromuscular blockade)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>nevirapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int474-nicardipine.htm">Nicardipine</a></td><td><p><span></span> <span>carbamazepine</span> <span>probably reduces effects of</span> <span>nicardipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span></span> <span>carbamazepine</span> <span>probably reduces effects of</span> <span>nifedipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int476-nimodipine.htm">Nimodipine</a></td><td><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>nimodipine</span> <span>(plasma concentration of <span>nimodipine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>olanzapine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>ondansetron</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>sometimes reduced by</span> <span>oxcarbazepine</span> <span>(but concentration of an active metabolite of <span>carbamazepine</span> may be increased), also plasma concentration of an active metabolite of <span>oxcarbazepine</span> often reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1101-paliperidone.htm">Paliperidone</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>paliperidone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int59-paracetamol.htm">Paracetamol</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly accelerates metabolism of</span> <span>paracetamol</span> <span>(also isolated reports of hepatotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly increases plasma concentration of</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of both drugs often reduced when </span> <span>carbamazepine</span> <span>given with</span> <span>phenytoin</span> <span>, also plasma concentration of <span>phenytoin</span> may be increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>posaconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>quetiapine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1195-retigabine.htm">Retigabine</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>retigabine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>reduced by</span> <span>rifabutin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int368-risperidone.htm">Risperidone</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>risperidone</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1102-rufinamide.htm">Rufinamide</a></td><td><p><span>plasma concentration of both drugs possibly reduced when </span> <span>carbamazepine</span> <span>given with</span> <span>rufinamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>simvastatin</span> <span>—consider increasing dose of <span>simvastatin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1144-stiripentol.htm">Stiripentol</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>carbamazepine</span> <span>increased by</span> <span>stiripentol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>telithromycin</span> <span>(avoid during and for 2 weeks after <span>carbamazepine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>theophylline</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>thyroid hormones</span> <span>(may increase requirements for <span>thyroid hormones</span> in hypothyroidism)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int857-tiagabine.htm">Tiagabine</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>tiagabine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int737-tibolone.htm">Tibolone</a></td><td><p><span></span> <span>carbamazepine</span> <span>accelerates metabolism of</span> <span>tibolone</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>tipranavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td><p><span></span> <span>carbamazepine</span> <span>often reduces plasma concentration of</span> <span>topiramate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int582-toremifene.htm">Toremifene</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly accelerates metabolism of</span> <span>toremifene</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces effects of</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int255-trazodone.htm">Trazodone</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>trazodone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>valproate</span> <span>, also plasma concentration of active metabolite of <span>carbamazepine</span> increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>vandetanib</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span> <span>carbamazepine</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>effects of </span> <span>carbamazepine</span> <span>enhanced by</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int768-vitamin-d.htm">Vitamin D</a></td><td><p><span></span> <span>carbamazepine</span> <span>possibly increases requirements for</span> <span>vitamin D</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>carbamazepine</span> <span>possibly reduces plasma concentration of</span> <span>voriconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1040-zonisamide.htm">Zonisamide</a></td><td><p><span></span> <span>carbamazepine</span> <span>reduces plasma concentration of</span> <span>zonisamide</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Ethosuximide</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>ethosuximide</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td class="cAI"><p><span>metabolism of </span> <span>ethosuximide</span> <span>inhibited by</span> <span>isoniazid</span> <span>(increased plasma concentration and risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>ethosuximide</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ethosuximide</span> <span>possibly reduced by</span> <span>phenytoin</span> <span>, also plasma concentration of <span>phenytoin</span> possibly increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>ethosuximide</span> <span>possibly increased by</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Gabapentin</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>gabapentin</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int98-morphine.htm">Morphine</a></td><td><p><span>bioavailability of </span> <span>gabapentin</span> <span>increased by</span> <span>morphine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Lamotrigine</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>lamotrigine</span> <span>often reduced by</span> <span>carbamazepine</span> <span>, also plasma concentration of an active metabolite of <span>carbamazepine</span> sometimes raised (but evidence is conflicting)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int665-desogestrel.htm">Desogestrel</a></td><td><p><span>plasma concentration of </span> <span>lamotrigine</span> <span>possibly increased by</span> <span>desogestrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>lamotrigine</span> <span>reduced by</span> <span>oestrogens</span> <span>—consider increasing dose of <span>lamotrigine</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>lamotrigine</span> <span>reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>lamotrigine</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>lamotrigine</span> <span>reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>lamotrigine</span> <span>possibly reduced by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td class="cAI"><p><span>plasma concentration of  </span> <span>lamotrigine</span> <span>increased by</span> <span>valproate</span> <span>(increased risk of toxicity—reduce <span>lamotrigine</span> dose)</span>  </p></td><td></td></tr></tbody></table><p><strong>Levetiracetam</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span></span> <span>levetiracetam</span> <span>possibly increases risk of</span> <span>carbamazepine</span> <span>toxicity</span>  </p></td><td></td></tr></tbody></table><p><strong>Oxcarbazepine</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span></span> <span>oxcarbazepine</span> <span>sometimes reduces plasma concentration of</span> <span>carbamazepine</span> <span>(but concentration of an active metabolite of <span>carbamazepine</span> may be increased), also plasma concentration of an active metabolite of <span>oxcarbazepine</span> often reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>oxcarbazepine</span> <span>possibly reduces plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>oxcarbazepine</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1153-eslicarbazepine.htm">Eslicarbazepine</a></td><td><p><span>avoidance of </span> <span>oxcarbazepine</span> <span>advised by manufacturer of</span> <span>eslicarbazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td class="cAI"><p><span></span> <span>oxcarbazepine</span> <span>reduces plasma concentration of</span> <span>imatinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>oxcarbazepine</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span></span> <span>oxcarbazepine</span> <span>increases plasma concentration of</span> <span>phenobarbital</span> <span>, also plasma concentration of an active metabolite of <span>oxcarbazepine</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>oxcarbazepine</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span>, also plasma concentration of an active metabolite of <span>oxcarbazepine</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>oxcarbazepine</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span> <span>oxcarbazepine</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of an active metabolite of </span> <span>oxcarbazepine</span> <span>sometimes reduced by</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Phenytoin</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>abacavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int551-acetazolamide.htm">Acetazolamide</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased by</span> <span>acetazolamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly reduced by chronic heavy consumption of</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>metabolism of </span> <span>phenytoin</span> <span>inhibited by</span> <span>amiodarone</span> <span>(increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>phenytoin</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td><p><span>effects of </span> <span>phenytoin</span> <span>enhanced by</span> <span>aspirin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased or decreased by</span> <span>benzodiazepines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int993-busulfan.htm">Busulfan</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>busulfan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of both drugs often reduced when </span> <span>phenytoin</span> <span>given with</span> <span>carbamazepine</span> <span>, also plasma concentration of <span>phenytoin</span> may be increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int550-carbonic-anhydrase-inhibitors.htm">Carbonic Anhydrase Inhibitors</a></td><td><p><span>increased risk of osteomalacia when </span> <span>phenytoin</span> <span>given with</span> <span>carbonic anhydrase inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int947-caspofungin.htm">Caspofungin</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>caspofungin</span> <span>—consider increasing dose of <span>caspofungin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int158-chloramphenicol.htm">Chloramphenicol</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>chloramphenicol</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int374-chlorpromazine.htm">Chlorpromazine</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased or decreased by</span> <span>chlorpromazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>ciclosporin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>metabolism of </span> <span>phenytoin</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased or decreased by</span> <span>ciprofloxacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int877-cisplatin.htm">Cisplatin</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly reduced by</span> <span>cisplatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>metabolism of </span> <span>phenytoin</span> <span>inhibited by</span> <span>clarithromycin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int408-clonazepam.htm">Clonazepam</a></td><td><p><span></span> <span>phenytoin</span> <span>often reduces plasma concentration of</span> <span>clonazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>clozapine</span> <span>(reduced plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1108-colesevelam.htm">Colesevelam</a></td><td><p><span>absorption of </span> <span>phenytoin</span> <span>possibly reduced by</span> <span>colesevelam</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </p></div></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>corticosteroids</span> <span>(reduced effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>coumarins</span> <span>(possibility of reduced anticoagulant effect, but enhancement also reported)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>dabigatran etexilate</span> <span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>darunavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased or decreased by</span> <span>diazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>reduced by</span> <span>diazoxide</span> <span>, also effect of <span>diazoxide</span> may be reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>diltiazem</span> <span>but also effect of <span>diltiazem</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int523-disulfiram.htm">Disulfiram</a></td><td class="cAI"><p><span>metabolism of </span> <span>phenytoin</span> <span>inhibited by</span> <span>disulfiram</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int212-doxycycline.htm">Doxycycline</a></td><td><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>doxycycline</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int830-enteral-foods.htm">Enteral Foods</a></td><td><p><span>absorption of </span> <span>phenytoin</span> <span>possibly reduced by</span> <span>enteral feeds</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1205-eribulin.htm">Eribulin</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>eribulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1153-eslicarbazepine.htm">Eslicarbazepine</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>eslicarbazepine</span> <span>, also plasma concentration of <span>phenytoin</span> increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td class="cAI"><p><span>effects of </span> <span>phenytoin</span> <span>enhanced by</span> <span>esomeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int281-ethosuximide.htm">Ethosuximide</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased by</span> <span>ethosuximide</span> <span>, also plasma concentration of <span>ethosuximide</span> possibly reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1031-etoposide.htm">Etoposide</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>etoposide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int471-felodipine.htm">Felodipine</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces effects of</span> <span>felodipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>fluconazole</span> <span>(consider reducing dose of <span>phenytoin</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int509-fluorouracil.htm">Fluorouracil</a></td><td><p><span>metabolism of </span> <span>phenytoin</span> <span>possibly inhibited by</span> <span>fluorouracil</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int603-fluvastatin.htm">Fluvastatin</a></td><td><p><span>combination of </span> <span>phenytoin</span> <span>with</span> <span>fluvastatin</span> <span>may increase plasma concentration of either drug (or both)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int860-folates.htm">Folates</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly reduced by</span> <span>folates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int542-furosemide.htm">Furosemide</a></td><td><p><span></span> <span>phenytoin</span> <span>antagonises effects of</span> <span>furosemide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>gefitinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>imatinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>indinavir</span> <span>, also plasma concentration of <span>phenytoin</span> possibly increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int758-influenza-vaccine.htm">Influenza Vaccine</a></td><td><p><span>effects of </span> <span>phenytoin</span> <span>enhanced by</span> <span>influenza vaccine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>irinotecan</span> <span>and its active metabolite</span>  </p></td><td></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td><p><span>metabolism of </span> <span>phenytoin</span> <span>possibly inhibited by</span> <span>isoniazid</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int472-isradipine.htm">Isradipine</a></td><td><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>isradipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>itraconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>lamotrigine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int891-leflunomide.htm">Leflunomide</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased by</span> <span>leflunomide</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</p></div></td></tr><tr><td><a href="bnf_int1032-levamisole.htm">Levamisole</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased by</span> <span>levamisole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces effects of</span> <span>levodopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>neurotoxicity may occur when </span> <span>phenytoin</span> <span>given with</span> <span>lithium</span> <span>without increased plasma concentration of <span>lithium</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>lopinavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>methadone</span> <span>(reduced effect and risk of withdrawal effects)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int511-methotrexate.htm">Methotrexate</a></td><td><p><span></span> <span>phenytoin</span> <span>increases antifolate effect of</span> <span>methotrexate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>methylphenidate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int170-metronidazole.htm">Metronidazole</a></td><td><p><span>metabolism of </span> <span>phenytoin</span> <span>possibly inhibited by</span> <span>metronidazole</span> <span>(increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to topical metronidazole preparations </p></div></td></tr><tr><td><a href="bnf_int254-mianserin.htm">Mianserin</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>mianserin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int299-miconazole.htm">Miconazole</a></td><td class="cAI"><p><span>anticonvulsant effect of </span> <span>phenytoin</span> <span>enhanced by</span> <span>miconazole</span> <span>(plasma concentration of <span>phenytoin</span> increased)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int847-modafinil.htm">Modafinil</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased by</span> <span>modafinil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int620-muscle-relaxants-non-depolarising.htm">Muscle Relaxants, non-depolarising</a></td><td><p><span></span> <span>phenytoin</span> <span>antagonises muscle relaxant effect of</span> <span>non-depolarising muscle relaxants</span> <span>(accelerated recovery from neuromuscular blockade)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>reduced by</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int476-nimodipine.htm">Nimodipine</a></td><td><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>nimodipine</span> <span>(plasma concentration of <span>nimodipine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>effects of </span> <span>phenytoin</span> <span>possibly enhanced by</span> <span>omeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>ondansetron</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>oxcarbazepine</span> <span>, also plasma concentration of an active metabolite of <span>oxcarbazepine</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int59-paracetamol.htm">Paracetamol</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly accelerates metabolism of</span> <span>paracetamol</span> <span>(also isolated reports of hepatotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>paroxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span></span> <span>phenytoin</span> <span>often increases plasma concentration of</span> <span>phenobarbital</span> <span>, plasma concentration of <span>phenytoin</span> often reduced but may be increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>posaconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int340-pyrimethamine.htm">Pyrimethamine</a></td><td class="cAI"><p><span>anticonvulsant effect of </span> <span>phenytoin</span> <span>antagonised by</span> <span>pyrimethamine</span> <span>, also increased antifolate effect</span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>quetiapine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1195-retigabine.htm">Retigabine</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>retigabine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td class="cAI"><p><span>metabolism of </span> <span>phenytoin</span> <span>accelerated by</span> <span>rifamycins</span> <span>(reduced plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>rilpivirine</span> <span>(plasma concentration of <span>rilpivirine</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>ritonavir</span> <span>, also plasma concentration of <span>phenytoin</span> possibly affected</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1102-rufinamide.htm">Rufinamide</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>rufinamide</span> <span>, also plasma concentration of <span>phenytoin</span> possibly increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased by</span> <span>sertraline</span> <span>, also plasma concentration of <span>sertraline</span> possibly reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1144-stiripentol.htm">Stiripentol</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>stiripentol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td class="cAI"><p><span>absorption of </span> <span>phenytoin</span> <span>reduced by</span> <span>sucralfate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int689-sulfinpyrazone.htm">Sulfinpyrazone</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>sulfinpyrazone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int203-sulfonamides.htm">Sulfonamides</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>possibly increased by</span> <span>sulfonamides</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>tacrolimus</span> <span>, also plasma concentration of <span>phenytoin</span> possibly increased</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>telithromycin</span> <span>(avoid during and for 2 weeks after <span>phenytoin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span> <span>phenytoin</span> <span>given with</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>thyroid hormones</span> <span>(may increase requirements in hypothyroidism), also plasma concentration of <span>phenytoin</span> possibly increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int857-tiagabine.htm">Tiagabine</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>tiagabine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int737-tibolone.htm">Tibolone</a></td><td><p><span></span> <span>phenytoin</span> <span>accelerates metabolism of</span> <span>tibolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly reduces plasma concentration of</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int275-tolbutamide.htm">Tolbutamide</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>transiently increased by</span> <span>tolbutamide</span> <span>(possibility of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>topiramate</span> <span>(also plasma concentration of <span>topiramate</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int582-toremifene.htm">Toremifene</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly accelerates metabolism of</span> <span>toremifene</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>trimethoprim</span> <span>(also increased antifolate effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased or possibly reduced when given with</span> <span>valproate</span> <span>, also plasma concentration of <span>valproate</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span> <span>phenytoin</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces effects of</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int287-vigabatrin.htm">Vigabatrin</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>reduced by</span> <span>vigabatrin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int768-vitamin-d.htm">Vitamin D</a></td><td><p><span></span> <span>phenytoin</span> <span>possibly increases requirements for</span> <span>vitamin D</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased by</span> <span>voriconazole</span> <span>, also <span>phenytoin</span> reduces plasma concentration of <span>voriconazole</span> (increase dose of <span>voriconazole</span> and also monitor for <span>phenytoin</span> toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span>plasma concentration of </span> <span>phenytoin</span> <span>increased or decreased by</span> <span>zidovudine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr><tr><td><a href="bnf_int1040-zonisamide.htm">Zonisamide</a></td><td><p><span></span> <span>phenytoin</span> <span>reduces plasma concentration of</span> <span>zonisamide</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Fosphenytoin</strong> belongs to <strong>Antiepileptics</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Fosphenytoin interactions as for phenytoin</p></div><p><strong>Tiagabine</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>tiagabine</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>tiagabine</span> <span>reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>tiagabine</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Topiramate</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>topiramate</span> <span>often reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int270-glibenclamide.htm">Glibenclamide</a></td><td><p><span></span> <span>topiramate</span> <span>possibly reduces plasma concentration of</span> <span>glibenclamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int530-hydrochlorothiazide.htm">Hydrochlorothiazide</a></td><td><p><span>plasma concentration of </span> <span>topiramate</span> <span>possibly increased by</span> <span>hydrochlorothiazide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span></span> <span>topiramate</span> <span>possibly affects plasma concentration of</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int267-metformin.htm">Metformin</a></td><td><p><span></span> <span>topiramate</span> <span>possibly increases plasma concentration of</span> <span>metformin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>topiramate</span> <span>accelerates metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>topiramate</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>topiramate</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span>(also plasma concentration of <span>topiramate</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>topiramate</span> <span>accelerates metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>hyperammonaemia and CNS toxicity reported when </span> <span>topiramate</span> <span>given with</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Valproate</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td><p><span>effects of </span> <span>valproate</span> <span>enhanced by</span> <span>aspirin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span></span> <span>valproate</span> <span>inhibits the metabolism of</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>valproate</span> <span>reduced by</span> <span>carbamazepine</span> <span>, also plasma concentration of active metabolite of <span>carbamazepine</span> increased</span>  </p></td><td></td></tr><tr><td><a href="bnf_int138-carbapenems.htm">Carbapenems</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>valproate</span> <span>reduced by</span> <span>carbapenems</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>metabolism of </span> <span>valproate</span> <span>inhibited by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int409-clobazam.htm">Clobazam</a></td><td><p><span>plasma concentration of </span> <span>valproate</span> <span>possibly increased by</span> <span>clobazam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int408-clonazepam.htm">Clonazepam</a></td><td><p><span>increased risk of side-effects when </span> <span>valproate</span> <span>given with</span> <span>clonazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>valproate</span> <span>possibly increases or decreases plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int592-colestyramine.htm">Colestyramine</a></td><td><p><span>absorption of </span> <span>valproate</span> <span>possibly reduced by</span> <span>colestyramine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>valproate</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td><p><span></span> <span>valproate</span> <span>possibly increases plasma concentration of</span> <span>diazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>metabolism of </span> <span>valproate</span> <span>possibly inhibited by</span> <span>erythromycin</span> <span>(increased plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int638-ethinylestradiol.htm">Ethinylestradiol</a></td><td><p><span>plasma concentration of </span> <span>valproate</span> <span>possibly reduced by</span> <span>ethinylestradiol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int281-ethosuximide.htm">Ethosuximide</a></td><td><p><span></span> <span>valproate</span> <span>possibly increases plasma concentration of</span> <span>ethosuximide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td class="cAI"><p><span></span> <span>valproate</span> <span>increases plasma concentration of</span> <span>lamotrigine</span> <span>(increased risk of toxicity—reduce <span>lamotrigine</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int413-lorazepam.htm">Lorazepam</a></td><td><p><span></span> <span>valproate</span> <span>possibly increases plasma concentration of</span> <span>lorazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td class="cAI"><p><span>increased risk of side-effects including neutropenia when </span> <span>valproate</span> <span>given with</span> <span>olanzapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td><p><span></span> <span>valproate</span> <span>sometimes reduces plasma concentration of an active metabolite of</span> <span>oxcarbazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span></span> <span>valproate</span> <span>increases plasma concentration of</span> <span>phenobarbital</span> <span>(also plasma concentration of <span>valproate</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>valproate</span> <span>increases or possibly decreases plasma concentration of</span> <span>phenytoin</span> <span>, also plasma concentration of <span>valproate</span> reduced</span>  </p></td><td></td></tr><tr><td><a href="bnf_int893-pivmecillinam.htm">Pivmecillinam</a></td><td class="cAI"><p><span>avoidance of </span> <span>valproate</span> <span>advised by manufacturer of</span> <span>pivmecillinam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td><p><span></span> <span>valproate</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1102-rufinamide.htm">Rufinamide</a></td><td><p><span></span> <span>valproate</span> <span>possibly increases plasma concentration of</span> <span>rufinamide</span> <span>(reduce dose of <span>rufinamide</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1034-sodium-benzoate.htm">Sodium Benzoate</a></td><td><p><span></span> <span>valproate</span> <span>possibly reduces effects of</span> <span>sodium benzoate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1033-sodium-phenylbutyrate.htm">Sodium Phenylbutyrate</a></td><td><p><span></span> <span>valproate</span> <span>possibly reduces effects of</span> <span>sodium phenylbutyrate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int885-temozolomide.htm">Temozolomide</a></td><td><p><span></span> <span>valproate</span> <span>increases plasma concentration of</span> <span>temozolomide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td><p><span>hyperammonaemia and CNS toxicity reported when </span> <span>valproate</span> <span>given with</span> <span>topiramate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span></span> <span>valproate</span> <span>possibly increases plasma concentration of</span> <span>zidovudine</span> <span>(increased risk of toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Sodium Valproate</strong> belongs to <strong>Antiepileptics</strong> but has no specific interaction information.</p><div class="cG"><p><strong>Note:</strong> Sodium valproate interactions as for valproate</p></div><p><strong>Vigabatrin</strong> belongs to <strong>Antiepileptics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>vigabatrin</span> <span>reduces plasma concentration of</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1195-retigabine.htm" title="Retigabine">Retigabine</a></li><li id="_bnf_int437-phenobarbital"><a href="bnf_int437-phenobarbital.htm" title="Phenobarbital">Phenobarbital</a></li><li><a href="bnf_int1153-eslicarbazepine.htm" title="Eslicarbazepine">Eslicarbazepine</a></li><li><a href="bnf_int1144-stiripentol.htm" title="Stiripentol">Stiripentol</a></li><li><a href="bnf_int1129-lacosamide.htm" title="Lacosamide">Lacosamide</a></li><li><a href="bnf_int1102-rufinamide.htm" title="Rufinamide">Rufinamide</a></li><li><a href="bnf_int1040-zonisamide.htm" title="Zonisamide">Zonisamide</a></li><li><a href="bnf_int277-carbamazepine.htm" title="Carbamazepine">Carbamazepine</a></li><li><a href="bnf_int281-ethosuximide.htm" title="Ethosuximide">Ethosuximide</a></li><li><a href="bnf_int282-gabapentin.htm" title="Gabapentin">Gabapentin</a></li><li><a href="bnf_int283-lamotrigine.htm" title="Lamotrigine">Lamotrigine</a></li><li><a href="bnf_int913-levetiracetam.htm" title="Levetiracetam">Levetiracetam</a></li><li><a href="bnf_int900-oxcarbazepine.htm" title="Oxcarbazepine">Oxcarbazepine</a></li><li id="_bnf_int284-phenytoin"><a href="bnf_int284-phenytoin.htm" title="Phenytoin">Phenytoin</a></li><li><a href="bnf_int857-tiagabine.htm" title="Tiagabine">Tiagabine</a></li><li><a href="bnf_int285-topiramate.htm" title="Topiramate">Topiramate</a></li><li id="_bnf_int286-valproate"><a href="bnf_int286-valproate.htm" title="Valproate">Valproate</a></li><li><a href="bnf_int287-vigabatrin.htm" title="Vigabatrin">Vigabatrin</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int911-pioglitazone.htm">Previous: Pioglitazone</a> | <a class="top" href="bnf_int276-antiepileptics.htm#">Top</a> | <a accesskey="]" href="bnf_int1195-retigabine.htm">Next: Retigabine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>